Abstract:Background and Aim: Clinical strains of microorganisms, including pathogenic yeast-like fungi (YLF), are resistant to currently used antifungal agents. Thus, it is relevant to study the combinations of existing antimicrobial drugs and a medicinal extract of plant origin (farnesol). In previous studies, farnesol showed a relatively strong anti-biofilm effect against Candida albicans. This study aimed to determine how much the resistance profile of non-biofilm microorganisms can change. Materials and Methods: Six clinical isolates of C. albicans and one reference strain were used to study the interaction of farnesol with the most used antimycotics. To determine the sensitivity of YLF to antimycotic drugs, such as nystatin (50 μg), amphotericin B (10 μg), ketoconazole (10 μg), clotrimazole (10 μg), voriconazole (10 μg), fluconazole (25 μg), miconazole (10 μg), and intraconazole (10 μg), the classic disk diffusion method was used. In the second stage, one of the six strains was used to simulate candidiasis of the gastrointestinal tract in an in vivo quail model. As an unusual experimental design, this study investigated the effects of pretreated C. albicans in quails, not the in vivo pathogenicity of C. albicans, after treatment with farnesol. Results: The resistance profiles of Candida strains did not improve with farnesol in all strains. All concentrations of farnesol (100, 50, and 25 μM) demonstrated a fungistatic effect (i.e., an increase in drug sensitivity) in 23 of 56 (7×8) cases (41%). The remaining 54% demonstrated no changes in the resistance to antifungal drugs or deterioration of the indicators in rare cases (5%). At 100 μM farnesol, sensitivity improved in 33 of 56 cases (59%). Candidiasis or the severity of clinical disease of the quail digestive tract developed to a lesser extent if fungi were treated with farnesol. Conclusion: Farnesol does not always show a positive result on single cells without biofilm in the laboratory. However, in a biofilm or an in vivo model with biofilms, farnesol can be considered a new antimycotic drug or an additive to existing antimycotics.

In Vitro Antifungal Activity of Farnesyltransferase Inhibitors Against Clinical Isolates of Aspergillus and Candida

Lonafarnib Synergizes with Azoles Against Aspergillus Spp. and Exophiala Spp.

Antifungal resistance mechanisms of Aspergillus.

Ram1 Gene, Encoding a Subunit of Farnesyltransferase, Contributes to Growth, Antifungal Susceptibility to Amphotericin B of Aspergillus Fumigatus

Chemical Investigation of a Co-Culture of Aspergillus Fumigatus D and Fusarium Oxysporum R1

In vitro antifungal activity analysis of Streptomyces sp. strain 196 against Candida albicans and Aspergillus flavus

In Vitro Susceptibilities of Worldwide Isolates of Intrapulmonary Aspergillus Species and Important Candida Species in Sterile Body Sites against Important Antifungals: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2017–2020

Design, Synthesis of Novel Antifungal Triazole Derivatives with High Activities Against Aspergillus Fumigatus

Synthesis and Biological Evaluation of Pentanedioic Acid Derivatives As Farnesyltransferase Inhibitors

Antifungal susceptibility of clinical Aspergillus fumigatus isolates in vitro

iTRAQ-based proteomic analysis of the interaction of A549 human lung epithelial cells with <i>Aspergillus fumigatus</i> conidia

In vitro antifungal susceptibility profile and genotypic characterization of clinical Aspergillus isolates in Eastern China on behalf of Eastern China Invasive Fungi Infection Group (ECIFIG)

Anti-Fungal Activity Of Different Drugs Against Aspergillus Fumigatus Infection

Molecular identification and antifungal susceptibility in clinical isolates of Aspergillus species

Antifungal and Antivirulence Activity of Vanillin and Tannic Acid Against Aspergillus fumigatus and Fusarium solani

In vitro antifungal activity of micafungin against clinical strains of Candida spp. and Aspergillus spp. isolated from China

Characterization of Therapeutic Targets from Aspergillus fumigates in response to Adjunctive Combination Therapy (Ketoconazole with EDTA)

In Vitro Susceptibility Testing of Aspergillus Spp. Against Voriconazole, Itraconazole, Posaconazole, Amphotericin B and Caspofungin

Molecular Docking, Design, Synthesis and Antifungal Activity Study of Novel Triazole Derivatives

Enhancement of the antifungal activity of some antimycotics by farnesol and reduction of Candida albicans pathogenicity in a quail model experiment

Combined Application of Tacrolimus with Cyproconazole, Hymexazol and Novel {2-(3-R-1 H-1,2,4-triazol-5-yl)phenyl}amines as Antifungals: In Vitro Growth Inhibition and In Silico Molecular Docking Analysis to Fungal Chitin Deacetylase